Worth Seeing!
Invest in Cases Systematically - Every stock is handpicked Start Buying Now Start Buying Now
mw4me logo
Talk to Us | Subscribe | Advisory Services

Top Pharma Companies in India by Market Capitalisation - Identify Top Performing Pharmaceutical Sector Companies for Investment Today

Sensex 73730.16
609.28 (-0.82%)

Pharma Sector Overview

Presently, India is the largest provider of generic medicines, occupying a market share of 20 percent with respect to global supply by volume and fulfils nearly 60 percent of global demand for vaccines. Indian pharmaceutical stocks even supply nearly 80 percent of antiretroviral drugs (used in combating AIDS) in the international markets.
There are several benefits of investing in pharma stocks:
  • Long-term profitability – Pharma stocks can be attractive to long-term investors in spite of the volatility. The ever rising industry size and healthcare becoming a critical part of life, investors can make good returns if they invest at the right time.
  • Exponential growth – Being the evolving industry that it is, innovation, scientific breakthroughs, and technological advances can bring in exponential growth for many pharma stocks.
×
×
Filter

Top Pharma Companies in India as on Apr-2024

|
 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks
Filter
Company Name
Market cap
(Rs. Cr.)
CMP
(Change %)
Latest
P/E
Latest
P/BV
5Y Sales
Gr.(%)
5Y Profit
Gr.(%)
DeciZen
More Info
1
Sun Pharmaceutical Industries Ltd.
3,60,920
(Large Cap)
1,504.25
(-1.07%)
40.96
5.85
10.69
26.54
Q V PT
2
Cipla Ltd.
1,13,794
(Large Cap)
1,406.25
(0.06%)
30.6
4.38
8.47
14.67
Q V PT
3
Divis Laboratories Ltd.
1,06,860
(Large Cap)
4,025.35
(4.81%)
73.73
7.82
14.82
15.00
Q V PT
4
Dr. Reddys Laboratories Ltd.
1,04,316
(Large Cap)
6,263.70
(0.75%)
19.84
3.86
11.55
36.08
Q V PT
5
Zydus Lifesciences Ltd.
95,381
(Large Cap)
948.20
(-0.29%)
32.26
5.09
7.68
-0.07
Q V PT
6
Mankind Pharma Ltd.
94,869
(Large Cap)
2,360
(-1.62%)
58.13
10.47
15.71
13.53
Q V PT
7
Torrent Pharmaceuticals Ltd.
91,057
(Large Cap)
2,691.25
(-0.04%)
60.86
12.72
10.09
20.94
Q V+ PT
8
Apollo Hospitals Enterprise Ltd.
89,988
(Large Cap)
6,260
(-1.96%)
91.56
12.1
-1.90
34.75
Q V+ PT
9
Max Healthcare Institute Ltd.
77,986
(Mid Cap)
802
(-0.11%)
73.46
9.54
21.42
0.00
Q V+ PT
10
Lupin Ltd.
73,642
(Mid Cap)
1,615.85
(1.31%)
40.44
5.23
1.04
9.19
Q V PT
11
Aurobindo Pharma Ltd.
66,278
(Mid Cap)
1,131.80
(2.56%)
32.84
3.35
4.49
-7.93
Q V PT
12
Alkem Laboratories Ltd.
58,605
(Mid Cap)
4,903.15
(0.65%)
34.64
5.45
11.39
9.10
Q V+ PT
13
Abbott India Ltd.
54,961
(Mid Cap)
25,800.05
(0.53%)
47.72
15.98
10.15
20.60
Q V+ PT
14
Global Health Ltd.
38,865
(Mid Cap)
1,438
(-0.14%)
110.38
14
7.84
44.84
Q V+ PT
15
Biocon Ltd.
36,858
(Mid Cap)
307
(5.25%)
18.22
3.21
-3.80
31.80
Q V PT
16
Glaxosmithkline Pharmaceuticals Ltd.
36,130
(Mid Cap)
2,132.75
(3.26%)
66.15
22.07
2.52
11.21
Q V+ PT
17
Ipca Laboratories Ltd.
33,961
(Mid Cap)
1,336.40
(0.66%)
61.11
5.3
12.58
17.37
Q V+ PT
18
Fortis Healthcare Ltd.
33,501
(Mid Cap)
442.25
(-0.24%)
251.1
3.71
9.81
0.00
Q V+ PT
19
Glenmark Pharmaceuticals Ltd.
30,478
(Small Cap)
1,078
(-0.14%)
N/A
3.43
7.44
-31.19
Q V PT
20
JB Chemicals & Pharmaceuticals Ltd.
28,929
(Small Cap)
1,861
(0.31%)
56.96
10.26
18.11
31.92
Q V+ PT
21
Gland Pharma Ltd.
28,479
(Mid Cap)
1,732
(-0.38%)
35.85
3.31
17.42
19.02
Q V PT
22
Syngene International Ltd.
28,107
(Mid Cap)
700.30
(0.19%)
60.1
6.69
17.55
15.81
Q V+ PT
23
Ajanta Pharma Ltd.
27,710
(Mid Cap)
2,200.70
(2.83%)
36.59
7.29
11.98
4.54
Q V PT
24
Narayana Hrudayalaya Ltd.
26,073
(Small Cap)
1,280
(1.03%)
33.45
9.6
14.68
62.83
Q V+ PT
25
Laurus Labs Ltd.
23,558
(Small Cap)
437.25
(2.81%)
142.77
5.65
24.05
38.61
Q V PT
26
Dr. Lal Pathlabs Ltd.
19,927
(Small Cap)
2,387.05
(2.40%)
53.1
10.25
11.55
11.64
Q V PT
27
Alembic Pharmaceuticals Ltd.
19,473
(Small Cap)
991
(-0.69%)
33.14
4.21
12.54
23.14
Q V PT
28
Pfizer Ltd.
19,192
(Small Cap)
4,187.50
(1.31%)
37.86
5.59
4.26
11.01
Q V PT
29
Sanofi India Ltd.
19,065
(Small Cap)
8,290
(1.72%)
31.06
19.78
0.57
9.48
Q V+ PT
30
Piramal Pharma Ltd.
18,826
(Small Cap)
142
(0.00%)
117.45
2.92
0.00
0.00
Q V PT
Prev 1

Want to pick best stocks Undervalued Pharma Stocks for High returns?

Check Now!
Screens:
AlphaCases All-Weather Stocks 5 Star Rated Stocks Best Nifty 50 Stocks Best Nifty Next 50 Stocks Best Nifty 500 Stocks Best SmallCap Stocks Dividend Opp. Stocks Nifty Financial Services Stocks
×
×

Pharma - Today's Top Gainers

Company Name CMP Price Change(%)
Medicamen Biotech
494.5017.84%
Biocon
3075.25%
Bliss GVS Pharma
122.554.97%
Divis Lab
4,025.354.81%
Jagsonpal Pharma
346.604.30%
View More

Pharma - Today's Top Losers

Company Name CMP Price Change(%)
Sun Pharma Adv. Res
258.25-4.99%
Solara Active Pharma
541.65-3.19%
NGL Fine-Chem
2,630.75-2.99%
Dishman Carbogen Amc
227.70-2.46%
Vimta Labs
545.85-2.30%
View More

News about Top Pharma Companies in India

Piramal Pharma informs about disclosure

Pursuant to Regulation 30 of the SEBI Listing Regulations, Piramal Pharma has informed that the Company has received on 26th April 2024 assessment orders from the Office of The Navi Mumbai Municipal Corporation, Cess Department (‘Orders’), levying penalty aggregating to Rs 3,500 under the Bombay Provincial Municipal Corporation (Cess on Entry of Goods) Rules, 1996. The Orders were passed in connection with the disclosure requirement of cess liability in returns for the pre-acquisition period 1st April, 2008 to 31st March, 2011 and 1st April, 2012 to 31st March, 2013 in the matter of Hemmo Pharmaceuticals, which amalgamated with the Company in August, 2022. The said Orders does not have any material impact on financials, operation or other activities of the Company.

The above information is a part of company’s filings submitted to BSE.

27 Apr, 2024

Zydus Lifesciences gets USFDA’s final approval for Tretinoin Cream

The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad, India
26 Apr, 2024

Divi's Laboratories surges on planning for capacity addition at manufacturing facility

The proposed facility is expected to be operational around January 2027
26 Apr, 2024

Laurus Lab informs about approval of audited financial results

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Lab has informed that the Board of Directors approved the Audited Standalone and Consolidated Financial Results of the Company for the Year ended March 31, 2024 and Limited Reviewed Financial Results of the Company for the Quarter ended March 31, 2024 at their meeting held on April 25, 2024, which are enclosed along with the Audit Reports (including Limited Review Reports) issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE and National Stock Exchange of India: www.bseindia.com and www.nseinda.com respectively. The Board Meeting commenced at 02.00 pm and concluded at 02.45 pm.

The above information is a part of company’s filings submitted to BSE.

25 Apr, 2024

Laurus Labs informs about investors presentation

Laurus Labs has informed that it enclosed the presentation to the Investors/Analysts on the Standalone and Consolidated Financial Results of the Company for the Quarter and year ended March 31, 2024, for the Investors/Analysts call scheduled on April 25, 2024, which was already intimated on April 18, 2024. The presentation is also being uploaded on the website of the Company www.lauruslabs.com.

The above information is a part of company’s filings submitted to BSE.


25 Apr, 2024

Laurus Labs informs about press release

Laurus Labs has informed that it enclosed the Press Release on the financial results for the quarter and year ended March 31, 2024.

The above information is a part of company’s filings submitted to BSE.


25 Apr, 2024

Track Now: 5 Star Companies, Large Cap Companies, Mid Cap Companies, Small Cap Companies, Nifty Microcap Companies, Top IT Companies, Tax saver funds, Analyze your Equity Funds, Nifty Index Funds

Trending on MoneyWorks4Me: Stock Reasearch Reports, How many stocks to own in portfolio?, Why PE Ratio is important?, How to Choose Good Stocks?, Types of Mutual Funds, Why funds future upside is more useful than past performance?

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2024.
Rank Company Market Capitalization 2024 (INR  crores)
1 Sun Pharmaceutical Industries Ltd. 3,60,920 Crore
2 Cipla Ltd. 1,13,794 Crore
3 Divis Laboratories Ltd. 1,06,860 Crore
4 Dr. Reddys Laboratories Ltd. 1,04,316 Crore
5 Zydus Lifesciences Ltd. 95,381 Crore
6 Mankind Pharma Ltd. 94,869 Crore
7 Torrent Pharmaceuticals Ltd. 91,057 Crore
8 Apollo Hospitals Enterprise Ltd. 89,988 Crore
9 Max Healthcare Institute Ltd. 77,986 Crore
10 Lupin Ltd. 73,642 Crore
Find best pharma stocks to buy now
Do you know?
Asking 3 Right Questions minimizes the
RISK of Stock Investing
To Know
Right Stock | Right Price | Right Allocation
Find best stocks to buy now

Top Pharma Companies FAQs Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA ROE
Sanofi India Ltd. (S) Very Good 8,290 19,065 31.61 20.13 21.47 51.69
Abbott India Ltd. (M) Very Good 25,800 54,961 47.98 16.07 32.71 31.69
Laurus Labs Ltd. (S) Very Good 437.2 23,558 146.7 5.73 32.25 21.71
Dr. Reddys Laboratories Ltd. (L) Very Good 6,264 1,04,316 19.95 3.88 12.08 20.88
Torrent Pharmaceuticals Ltd. (L) Very Good 2,691 91,057 60.95 12.73 29.22 20.23

Based on the past year's gain, the best performing stocks are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) Yearly gain (%)
Lupin Ltd. (M) Somewhat Good 1,616 73,642 128.2
Glenmark Pharmaceuticals Ltd. (S) Somewhat Good 1,078 30,478 107.1
Ipca Laboratories Ltd. (M) Very Good 1,336 33,961 91.04
Aurobindo Pharma Ltd. (M) Very Good 1,132 66,278 84.23
Zydus Lifesciences Ltd. (L) Very Good 948.2 95,381 83.54
View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Sales Growth (%)
Laurus Labs Ltd. (S) Very Good 437.2 23,558 146.7 5.73 32.25 24.05
Granules India Ltd. (S) Somewhat Good 426.4 10,284 22.16 3.41 13.40 19.01
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,861 28,929 57.15 10.29 33.76 18.11
Gland Pharma Ltd. (M) Very Good 1,732 28,479 35.55 3.28 20.21 17.42
Mankind Pharma Ltd. (L) Very Good 2,360 94,869 57.49 10.36 39.70 15.71

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Profit Growth (%)
Laurus Labs Ltd. (S) Very Good 437.2 23,558 146.7 5.73 32.25 38.61
Dr. Reddys Laboratories Ltd. (L) Very Good 6,264 1,04,316 19.95 3.88 12.08 36.08
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,861 28,929 57.15 10.29 33.76 31.92
Biocon Ltd. (M) Somewhat Good 307.0 36,858 19.24 3.39 99.21 31.80
Granules India Ltd. (S) Somewhat Good 426.4 10,284 22.16 3.41 13.40 31.51
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now
SEBI Registered: Investment Adviser - INA000013323
Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.
Compliance Officer:
Name: Shrikant Jagtap
Email : shrikant.jagtap@moneyworks4me.com
Mobile No: +91 97638 00745
Grievance officer:
Name: Mukta Vaze
Email : mukta.vaze@moneyworks4me.com
Mobile No:+91 98609 19463
Principal Officer:
Name: Atharva Bhide
Email : atharva.bhide@moneyworks4me.com
Mobile No:+91 91758 99463
Sitemap play-store Download APP play-store Download APP
linkedin facebook twitter youtube insta telegram
Address: MoneyWorks4Me Investment Advisers, B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Complaints: Register a Complaint | Complaint status | Cancellation and Refund Policy | PML Act | Grievance Redressal Process | Investor charter | Terms & Conditions | Disclaimer | Disclosure
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.